In a multicenter trial, the use of radiation-emitting metallic stents (REMS) combined with hepatic arterial infusion chemotherapy (HAIC) significantly enhanced overall survival (10.2 months vs. 6.7 months) and time to symptomatic progression (8.6 months vs. 5.4 months) compared to self-expandable metallic stents (SEMS) with HAIC in patients with unresectable Bismuth type III or IV perihilar cholangiocarcinoma. Both groups had similar jaundice relief rates and adverse event occurrences.
Journal Article by Chen Q, Ge NJ (…) Lu J et 19 al. in Int J Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.